Berenberg Bank Forecasts Strong Price Appreciation for Haleon (LON:HLN) Stock

Haleon (LON:HLN) had its price objective hoisted by investment analysts at Berenberg Bank from GBX 456 ($5.79) to GBX 457 ($5.81) in a report issued on Friday,Digital Look reports. The firm currently has a “buy” rating on the stock. Berenberg Bank’s target price points to a potential upside of 11.87% from the stock’s current price.

Haleon Stock Up 3.3 %

Haleon stock traded up GBX 13.21 ($0.17) during midday trading on Friday, reaching GBX 408.51 ($5.19). The company’s stock had a trading volume of 17,311,160 shares, compared to its average volume of 26,942,223. Haleon has a 52-week low of GBX 308.37 ($3.92) and a 52-week high of GBX 411.40 ($5.23). The stock has a market capitalization of £36.87 billion, a P/E ratio of 34.36, a PEG ratio of 1.49 and a beta of 0.19. The company has a debt-to-equity ratio of 53.36, a current ratio of 0.84 and a quick ratio of 0.93. The stock’s 50-day simple moving average is GBX 380.01 and its 200-day simple moving average is GBX 379.31.

Haleon (LON:HLN) last released its earnings results on Friday, February 28th. The company reported GBX 15.80 ($0.20) earnings per share (EPS) for the quarter. Haleon had a return on equity of 6.54% and a net margin of 9.66%. On average, sell-side analysts expect that Haleon will post 19.5033282 EPS for the current year.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s portfolio spans five global categories including Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health and Digestive Health and other.